Apelin Receptor Modulation Therapy

📖 Wiki Page

therapeutic1064 wordssynced 2026-04-02

Apelin Receptor Modulation Therapy

Overview

flowchart TD Apelin_Receptor_Modulation_The["Apelin Receptor Modulation Therapy"] Apelin_Receptor_Modulation_The["Therapy"] Apelin_Receptor_Modulation_The -->|"related to"| Apelin_Receptor_Modulation_The style Apelin_Receptor_Modulation_The fill:#81c784,stroke:#333,color:#000 Apelin_Receptor_Modulation_The["table"] Apelin_Receptor_Modulation_The -->|"related to"| Apelin_Receptor_Modulation_The style Apelin_Receptor_Modulation_The fill:#81c784,stroke:#333,color:#000 Apelin_Receptor_Modulation_The["class"] Apelin_Receptor_Modulation_The -->|"related to"| Apelin_Receptor_Modulation_The style Apelin_Receptor_Modulation_The fill:#81c784,stroke:#333,color:#000 style Apelin_Receptor_Modulation_The fill:#4fc3f7,stroke:#333,color:#000

...

Apelin Receptor Modulation Therapy

Overview

Mermaid diagram (expand to render)

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Apelin Receptor Modulation Therapy</th>
</tr>
<tr>
<td class="label">Peptide</td>
<td>Amino Acids</td>
</tr>
<tr>
<td class="label">Apelin-36</td>
<td>36</td>
</tr>
<tr>
<td class="label">Apelin-16</td>
<td>16</td>
</tr>
<tr>
<td class="label">Apelin-13</td>
<td>13</td>
</tr>
<tr>
<td class="label">Apelin-12</td>
<td>12</td>
</tr>
<tr>
<td class="label">Effect</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Amyloid Reduction</td>
<td>Enhanced autophagy</td>
</tr>
<tr>
<td class="label">Tau Modification</td>
<td>GSK-3beta inhibition</td>
</tr>
<tr>
<td class="label">Synaptic Protection</td>
<td>CREB/BDNF</td>
</tr>
<tr>
<td class="label">Cognitive Improvement</td>
<td>Multiple</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Type</td>
</tr>
<tr>
<td class="label">Apelin-13</td>
<td>Peptide</td>
</tr>
<tr>
<td class="label">\[Pyr^1\]-Apelin-13</td>
<td>Peptide</td>
</tr>
<tr>
<td class="label">Small Molecule Agonists</td>
<td>Small molecule</td>
</tr>
<tr>
<td class="label">AAV-APJ</td>
<td>Gene therapy</td>
</tr>
<tr>
<td class="label">Strategy</td>
<td>Approach</td>
</tr>
<tr>
<td class="label">Intranasal</td>
<td>Direct to CNS</td>
</tr>
<tr>
<td class="label">AAV Vector</td>
<td>Gene delivery</td>
</tr>
<tr>
<td class="label">Exosomes</td>
<td>Cell-derived</td>
</tr>
<tr>
<td class="label">Small Molecule</td>
<td>Oral delivery</td>
</tr>
</table>

Apelin receptor modulation represents an emerging therapeutic strategy for neurodegenerative diseases. The apelin-APJ system is a pleiotropic signaling pathway that influences multiple processes critical to neurodegeneration, including autophagy, blood-brain barrier (BBB) integrity, neuroinflammation, mitochondrial function, and neuronal survival["@obrien2012"][@cook2014].

Apelin is a family of bioactive peptides (apelin-12, apelin-13, apelin-16, apelin-36) that signal through the APJ receptor (APLNR), a G protein-coupled receptor widely expressed in the central nervous system. The apelin-APJ axis has been implicated in the pathogenesis of Alzheimer's disease, Parkinson's disease, Amyotrophic Lateral Sclerosis, and atypical parkinsonian disorders including corticobasal syndrome and progressive supranuclear palsy.

The Apelin-APJ System

Apelin Peptides

The apelin precursor is a 77-amino acid preproprotein that is cleaved to generate various active fragments:

Apelin-13 and its stable analog \[Pyr^1\]-apelin-13 are the most studied for therapeutic applications due to their high receptor affinity and stability.

APJ Receptor (APLNR)

The APJ receptor is a Class A GPCR that:

Couples to multiple G proteins (Gαi/o, Gαq)
Activates PI3K/AKT, MAPK/ERK, and AMPK pathways
Undergoes ligand-dependent and independent (constitutive) signaling
Dimerizes with other receptors (e.g., angiotensin AT1 receptor)

Mechanisms of Neuroprotection

Autophagy Enhancement

Apelin-13 promotes autophagy through AMPK and mTOR signaling pathways[@tang2019]:

AMPK Activation: Phosphorylates AMPK, enhancing TFEB nuclear translocation

mTOR Inhibition: Reduces mTORC1 activity, relieving autophagy suppression

Autophagosome Formation: Increases LC3-II conversion and autophagosome numbers

Lysosomal Function: Enhances lysosomal biogenesis and function

This autophagy enhancement is particularly relevant for:

Alzheimer's Disease: Clearing amyloid-beta and tau aggregates
Parkinson's Disease: Removing alpha-synuclein aggregates
ALS: Degrading TDP-43 and SOD1 aggregates

Blood-Brain Barrier Protection

Apelin-13 protects BBB integrity through multiple mechanisms[@lu2018]:

Tight Junction Preservation: Maintains claudin-5 and ZO-1 expression
Endothelial Survival: Promotes endothelial cell survival via AKT
Reduced Permeability: Decreases BBB leakage in injury models
Angiogenesis Regulation: Modulates new vessel formation

BBB protection is critical for:

Limiting neurotoxin entry into the CNS
Maintaining CNS immune privilege
Ensuring proper drug delivery

Neuroinflammation Modulation

Apelin modulates neuroinflammation through[@chen2024]:

Microglial Polarization: Shifts microglia toward anti-inflammatory (M2) phenotype

Cytokine Reduction: Decreases TNF-α, IL-1β, IL-6 production

NF-κB Inhibition: Reduces pro-inflammatory signaling

T Cell Regulation: Modulates CNS immune responses

Mitochondrial Protection

Apelin-13 promotes mitochondrial health:

Biogenesis: Increases PGC-1α expression and mitochondrial replication
Fusion: Enhances Mfn1/2 and OPA1-mediated fusion
Mitophagy: Facilitates PINK1/Parkin-independent mitophagy
ATP Production: Improves mitochondrial respiration

Neuronal Survival

Neuroprotective signaling through:

AKT Pathway: Phosphorylation of AKT and downstream targets (GSK-3β, BAD)
ERK Pathway: Activation promotes neuronal survival
CREB Activation: Enhances BDNF expression and synaptic plasticity
Calcium Regulation: Modulates calcium homeostasis

Role in Specific Diseases

Alzheimer's Disease

Apelin-13 has multiple beneficial effects in AD models[@xu2016][@wang2023]:

Parkinson's Disease

Apelin-13 shows neuroprotection in PD models[@yang2017]:

Dopaminergic Protection: Preserves tyrosine hydroxylase neurons
Mitochondrial Rescue: Improves complex I function
Motor Improvement: Reduces akinesia in MPTP models
Alpha-Syn Clearance: Autophagy enhancement

Amyotrophic Lateral Sclerosis

In ALS models, apelin shows[@jiang2018]:

Motor Neuron Protection: Reduces motor neuron loss
Glial Modulation: Affects astrocyte and microglial reactivity
SOD1 Clearance: Enhances mutant SOD1 removal
Extended Survival: Improves lifespan in transgenic models

CBS/PSP (4R-Tauopathies)

Apelin modulation may benefit 4R-tauopathies:

Tau Clearance: Autophagy enhancement aids tau removal
BBB Protection: Important for brainstem regions affected in PSP
Neuroinflammation: Reduces tau-induced inflammation

Therapeutic Approaches

Apelin Receptor Agonists

Apelin Peptide Analogs

Modified analogs under development:

PEGylated apelin: Extended half-life
D-amino acid analogs: Protease resistance
Small peptide fragments: Blood-brain barrier penetration

Clinical Trials

Currently limited clinical trial data for CNS applications:

(TBD): Apelin infusion in heart failure (not CNS)

(TBD): APJ agonist in pulmonary hypertension

No registered trials for neurodegenerative indications

Challenges

BBB Penetration: Apelin peptides do not cross BBB efficiently
Stability: Rapid degradation by proteases
Receptor Desensitization: Chronic exposure reduces signaling
Dose Timing: Optimal window for intervention unclear

Delivery Strategies

Cross-References

[Autophagy-Lysosomal Pathway](/mechanisms/autophagy-lysosomal-pathway)
[Blood-Brain Barrier](/mechanisms/blood-brain-barrier)
[Neuroinflammation](/mechanisms/neuroinflammation)
[Mitochondrial Dysfunction](/mechanisms/mitochondrial-dysfunction)
[Alzheimer's Disease](/diseases/alzheimers-disease)
[Parkinson's Disease](/diseases/parkinsons-disease)
[Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis)
[Progressive Supranuclear Palsy](/diseases/progressive-supranuclear-palsy)
[Corticobasal Syndrome](/diseases/corticobasal-degeneration)

External Links

[NCBI Gene - APLNR](https://www.ncbi.nlm.nih.gov/gene/187)
[UniProt - APJ Receptor](https://www.uniprot.org/uniprot/Q99705)
[PubMed - Apelin Neurodegeneration](https://pubmed.ncbi.nlm.nih.gov/?term=apelin+neurodegeneration)

References

[O'Brien et al., Apelin-13 and apelin-36 in brain function (2012)](https://pubmed.ncbi.nlm.nih.gov/22948068/). Reviews apelin peptide functions in the CNS.

[Cook et al., Apelin and neurodegeneration (2014)](https://pubmed.ncbi.nlm.nih.gov/24823917/). Documents apelin's role in neurodegenerative disease models.

[Xu et al., Apelin in Alzheimer's disease (2016)](https://pubmed.ncbi.nlm.nih.gov/26854214/). Shows apelin-13 effects on amyloid pathology.

[Yang et al., Apelin-13 neuroprotection in Parkinson's disease (2017)](https://pubmed.ncbi.nlm.nih.gov/28284608/). Demonstrates dopaminergic neuroprotection.

[Lu et al., Apelin-13 and blood-brain barrier (2018)](https://pubmed.ncbi.nlm.nih.gov/29337695/). Documents BBB protective effects.

[Jiang et al., Apelin in ALS (2018)](https://pubmed.ncbi.nlm.nih.gov/29555134/). Shows benefits in ALS models.

[Tang et al., Apelin-13 and autophagy in neurodegeneration (2019)](https://pubmed.ncbi.nlm.nih.gov/31094605/). Details autophagy enhancement mechanisms.

[Zhou et al., Apelin receptor agonists for neuroprotection (2021)](https://pubmed.ncbi.nlm.nih.gov/33907933/). Reviews therapeutic potential.

[Wang et al., Apelin-13 in tauopathy models (2023)](https://pubmed.ncbi.nlm.nih.gov/36796987/). Shows effects on tau pathology.

[Chen et al., Apelin receptor modulation and neuroinflammation (2024)](https://pubmed.ncbi.nlm.nih.gov/38441302/). Documents anti-inflammatory effects.

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Bacterial Enzyme-Mediated Dopamine Precursor Synthesis](/hypothesis/h-7bb47d7a) — 0.44 · Target: TH, AADC
[Hippocampal CA3-CA1 circuit rescue via neurogenesis and synaptic preservation](/hypothesis/h-856feb98) — 0.73 · Target: BDNF
[Vagal Afferent Microbial Signal Modulation](/hypothesis/h-ee1df336) — 0.71 · Target: GLP1R, BDNF
[Vocal Cord Neuroplasticity Stimulation](/hypothesis/h-e0183502) — 0.48 · Target: CHR2/BDNF
[CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — 0.79 · Target: CYP46A1
[Gamma entrainment therapy to restore hippocampal-cortical synchrony](/hypothesis/h-bdbd2120) — 0.77 · Target: SST
[Circadian Glymphatic Entrainment via Targeted Orexin Receptor Modulation](/hypothesis/h-9e9fee95) — 0.77 · Target: HCRTR1/HCRTR2
[Selective Acid Sphingomyelinase Modulation Therapy](/hypothesis/h-de0d4364) — 0.77 · Target: SMPD1

Related Analyses:

[Lipid raft composition changes in synaptic neurodegeneration](/analysis/SDA-2026-04-01-gap-lipid-rafts-2026-04-01) 🔄
[TDP-43 phase separation therapeutics for ALS-FTD](/analysis/SDA-2026-04-01-gap-006) 🔄
[Synaptic pruning by microglia in early AD](/analysis/SDA-2026-04-01-gap-v2-691b42f1) 🔄
[Blood-brain barrier transport mechanisms for antibody therapeutics](/analysis/SDA-2026-04-01-gap-008) 🔄
[Perivascular spaces and glymphatic clearance failure in AD](/analysis/SDA-2026-04-01-gap-v2-ee5a5023) 🔄

📖 View canonical wiki page →

Apelin Receptor Modulation Therapy

Apelin Receptor Modulation Therapy

Overview

Apelin Receptor Modulation Therapy

Overview

The Apelin-APJ System

Apelin Peptides

APJ Receptor (APLNR)

Mechanisms of Neuroprotection

Autophagy Enhancement

Blood-Brain Barrier Protection

Neuroinflammation Modulation

Mitochondrial Protection

Neuronal Survival

Role in Specific Diseases

Alzheimer's Disease

Parkinson's Disease

Amyotrophic Lateral Sclerosis

CBS/PSP (4R-Tauopathies)

Therapeutic Approaches

Apelin Receptor Agonists

Apelin Peptide Analogs

Clinical Trials

Challenges

Delivery Strategies

Cross-References

See Also

External Links

References

Related Hypotheses